ALD-R491 / Aluda Pharma - LARVOL DELTA

The Vimentin-Targeting Drug ALD-R491 Partially Reverts the Epithelial-to-Mesenchymal Transition and Vimentin Interactome of Lung Cancer Cells. (PubMed, Cancers (Basel)) - " These findings present many new interactors of intermediate filaments, describe how EMT and vimentin filament dynamics influence the intermediate filament interactome, and present ALD-R491 as a possible EMT-inhibitor. The observations support the hypothesis that the dynamic turnover of vimentin filaments and their interacting proteins govern mesenchymal cell migration, EMT, cell invasion, and cancer metastasis."

Journal • Lung Cancer • Oncology • Solid Tumor • TGFB1 • VIM

The Vimentin-Targeting Drug ALD-R491 Partially Reverts the Epithelial-to-Mesenchymal Transition and Vimentin Interactome of Lung Cancer Cells (Multidisciplinary Digital Publishing Institute) - "TGF-β1 increased cell spreading and cell migration speed, and changed a positive correlation between cell migration speed and persistence to negative. ALD-R491 reversed these mesenchymal phenotypes to epithelial and the binding of RNA-binding proteins, including SON."

Preclinical • Lung Cancer

Therapeutic targeting of vimentin by ALD-R491 impacts multiple pathogenic processes to attenuate acute and chronic colitis in mice. (PubMed, Biomed Pharmacother) - "Targeting vimentin exhibits significant therapeutic effects on various facets of IBD pathogenesis, representing a compelling approach for the development of highly effective treatments in IBD."

Journal • Preclinical • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • CLDN5 • FOXP3 • IL10 • IL17A • IL1B • IL22 • IL6 • MUC2 • TJP1 • TNFA • VIM

ALD-R491 regulates vimentin filament stability and solubility, cell contractile force, cell migration speed and directionality. (PubMed, Front Cell Dev Biol) - "Taken together, these results indicate that the stability of vimentin filaments and the soluble pool of vimentin regulate the speed and directionality of cell migration and the capacity of cells to migrate in a mechanically cohesive manner. These observations suggest that the stability of vimentin filaments governs the adhesive, physical and migratory properties of cells, and expands our understanding of vimentin functions in health and disease, including cancer metastasis."

Journal • Oncology • VIM

A Vimentin-Targeting Oral Compound with Host-Directed Antiviral and Anti-Inflammatory Actions Addresses Multiple Features of COVID-19 and Related Diseases. (PubMed, mBio) - "In rats, ALD-R491 also reduced bleomycin-induced lung injury and fibrosis. Unlike virus-directed therapeutics that may lose efficacy due to viral mutations, and immunosuppressants that require ideal timing to be effective, this agent, with its unique host-directed antiviral and anti-inflammatory actions, can work against all variants of the virus, be effective during all stages of the disease, and even resolve post-disease damage and complications. Further development of the compound will provide an important tool in the fight against COVID-19 and its complications, as well as future outbreaks of new viruses."

Journal • Fibrosis • Immunology • Infectious Disease • Inflammation • Novel Coronavirus Disease • Respiratory Diseases • VIM

Aluda Pharmaceuticals announces peer-reviewed publication on ALD-R491, an Exosome Release Inhibitor and novel oncology mechanism (PRNewswire) - "Aluda Pharmaceuticals...announced the publication of an article in a peer reviewed journal describing a novel mechanism of Exosome Release Inhibition (ExoRI) for the treatment of a broad range of cancers....Aluda's paper, entitled A Small Vimentin-Binding Molecule Blocks Cancer Exosome Release and Reduces Cancer Cell Mobility, appears in the journal Frontiers in Pharmacology, and describes the exosome release inhibition action of ALD-R491 through multiple in vitro models..."

Preclinical • Oncology